DE refers to the exemption of medical devices intended for marketing from regulatory requirements, allowing clinical trials to be conducted on such devices...
APHRS and the Society for Cardiac Robotic Navigation will host a joint session on September 2, 2023, during the APHRS annual congress. The joint session in...
Uro-G offers a viewing angle of 120°, both 210° upward and 130° downward motion angles, and a 90° angle of rotation clockwise and countercl...
Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broaden...
Under the collaboration, Boostimmune will have access to WuXi XDC's fully integrated, one-stop bioconjugate platform and extensive expertise in industry-le...
The consistency evaluation of generic drugs evaluates approved generic drugs based on the principle that generic drugs need to reach the same level of qual...
GenScript Biotech, the world's leading life-science research tools and services provider, and T-MAXIMUM Biotech, a biotechnology company pioneering univers...
SHP2 is a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signaling with the downstream RAS/MAPK pathway to regulate cellular ...
Event co-organizer the Taiwan Bio Industry Organization (Taiwan BIO), stated that international participation was notably higher this year due to the lifti...
Moitreyee Chatterjee-Kishore, PhD, MBA, Senior Vice President and Head of Immuno-Oncology Development, Astellas"China accounts for nearly half of...
The GMP release of its first DS facility in China enhances WuXi Vaccines' capability in providing global partners with comprehensive end-to-end solutions, ...
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization ...
"We are excited for achieving this important milestone, which also marked the first step to what we hope will ultimately allow us to bring an innovative ca...
It is a multi-center, open-label clinical study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab. Entry criteria include ...
© 2025 Biopharma Boardroom. All Rights Reserved.
